Drug Approval | October 14, 2024
Indoco Remedies receives OAI status from USFDA for Goa plant 2 & 3
Indoco is comprehensively working on the remedial action plan
Indoco is comprehensively working on the remedial action plan
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
We now rank 3rd in pharmaceutical production by volume and 14th by value
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Strategic focus on COCO-model with a nationwide reach of 501 stores
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
he company will focus on production of any pharmaceutical and biotechnological products
USFDA completes PAI of Lupin’s biotech facility in Pune
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
